ZypAdhera ® (olanzapine pamoate monohydrate)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: ZypAdhera Summary of Product Characteristics (SmPC)

ZypAdhera® (olanzapine pamoate): Oral Supplementation (label)

Oral olanzapine supplementation is not required, but if clinically necessary, the combined dose from olanzapine pamoate and oral olanzapine should not exceed the corresponding maximum oral olanzapine dose of 20 mg/day.

Information from the Summary of Product Characteristics

Supplementation with oral olanzapine was not authorised in double-blind clinical studies.1

Due to the slow dissolution of the olanzapine pamoate salt, which provides a slow continuous release of olanzapine that is complete approximately six to eight months after the last injection, supervision by a clinician, especially during the first 2 months after discontinuation of olanzapine pamoate, is needed when switching to another antipsychotic product and is considered medically appropriate.1

References

1. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.

Date of Last Review: May 01, 2019


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request